Stock 4536 SANTEN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Santen Pharmaceutical Co., Ltd. Stock

Equities

4536

JP3336000009

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 02:34:42 2024-04-19 am EDT 		5-day change 1st Jan Change
1,452 JPY +0.66% Intraday chart for Santen Pharmaceutical Co., Ltd. -0.17% +3.38%
Mar. 26 Santen Pharmaceutical to Cancel 12 Million Treasury Shares MT
Mar. 25 Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024 CI

Financials

Sales 2024 * 301B 1.95B Sales 2025 * 292B 1.89B Capitalization 525B 3.4B
Net income 2024 * 31.74B 205M Net income 2025 * 33.24B 215M EV / Sales 2024 * 1.78 x
Net Debt 2024 * 10.05B 65.02M Net cash position 2025 * 14.69B 95.05M EV / Sales 2025 * 1.75 x
P/E ratio 2024 *
15.9 x
P/E ratio 2025 *
15.7 x
Employees 4,144
Yield 2024 *
2.27%
Yield 2025 *
2.31%
Free-Float 93.7%
More Fundamentals * Assessed data

Chart Santen Pharmaceutical Co., Ltd.

Dynamic Chart

Latest news about Santen Pharmaceutical Co., Ltd.

Santen Pharmaceutical to Cancel 12 Million Treasury Shares MT
Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024 CI
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023. CI
Santen Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 11, 2023, has closed with 12,571,400 shares, representing 3.38% for ¥16,178.35 million. CI
Santen Pharmaceutical's Returns to the Black in Fiscal Nine Months MT
Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024 CI
Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,700 Yen From 1,650 Yen, Keeps at Buy MT
Santen Pharmaceutical Further Repurchases Shares for Over 1 Billion Yen MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023. CI
Santen Pharmaceutical Buys Back Nearly 2 Billion Yen of Shares MT
Santen Pharmaceutical’s Fiscal H1 EPS Increases to 69.68 Yen as Net Sales Rise 13.1% to 145.81 Billion Yen; Declares Interim Dividend of 16 Yen Per Share, Maintains Forecast MT
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024 CI
Santen Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on November 30, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024 CI
Santen Pharmaceutical Buys Back 523,400 shares for 772.6 Million Yen in September MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023. CI
More news

Analyst Recommendations on Santen Pharmaceutical Co., Ltd.

Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,700 Yen From 1,650 Yen, Keeps at Buy MT
Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,650 Yen From 1,400 Yen, Keeps at Buy MT
Jefferies Adjusts Santen Pharmaceutical's Price Target to 1,400 Yen From 1,300 Yen, Keeps at Buy MT
Santen Pharmaceutical : Receives Financing from the Development Bank of Japan based on "DBJ Environmental Rating" PU
More recommendations

Press releases Santen Pharmaceutical Co., Ltd.

Santen Pharmaceutical : and Bayer Yakuhin Launch Ophthalmic VEGF Inhibitor Eylea®8mg Solution for Intravitreal Injection 114.3 mg/mL PU
Santen Pharmaceutical : Positioned for Further Growth in China Following Completion of Vision Park PU
Santen Pharmaceutical : obtains manufacturing and marketing approval in Japan for Alesion® eyelid cream (epinastine hydrochloride), a new treatment for allergic conjunctivitis PU
Santen Pharmaceutical : Announces Change of Representative Director of the Board PU
Santen Pharmaceutical : Announces Cancellation of Treasury Shares PU
More press releases

News in other languages on Santen Pharmaceutical Co., Ltd.

ETF der Woche: Back to the Roots
ETF de la semaine : Retour aux fondamentaux
ETF van de week: terug naar de basis
L'ETF della settimana: ritorno ai fondamentali
Nicox S A : A suivre aujourd'hui
More news

Quotes and Performance

1 day+0.66%
1 week-0.17%
Current month-5.47%
1 month-0.31%
3 months-0.92%
6 months+11.35%
Current year+3.38%
More quotes

Highs and lows

1 week
1 414.00
Extreme 1414
1 463.50
1 month
1 394.50
Extreme 1394.5
1 548.00
Current year
1 394.50
Extreme 1394.5
1 589.50
1 year
1 061.00
Extreme 1061
1 589.50
3 years
956.00
Extreme 956
1 718.00
5 years
956.00
Extreme 956
2 234.00
10 years
897.00
Extreme 897
2 234.00
More quotes

Managers and Directors - Santen Pharmaceutical Co., Ltd.

Managers TitleAgeSince
Takeshi Ito CEO
 Chief Executive Officer 64 82-03-31
Kazuo Koshiji DFI
 Director of Finance/CFO - -
Akira Kurokawa CHM
 Chairman 71 77-03-31
Members of the board TitleAgeSince
Akira Kurokawa CHM
 Chairman 71 77-03-31
Kanoko Oishi BRD
 Director/Board Member 63 15-05-31
Noboru Kotani BRD
 Director/Board Member 67 22-06-23
More insiders

ETFs positioned on Santen Pharmaceutical Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
NOMURA NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY ETF Nomura NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY
1.22% 15 M€ +4.29%
HARTFORD MULTIFACTOR DEVELOPED MARKETS (EX-US) ETF - USD ETF Hartford Multifactor Developed Markets (ex-US) ETF - USD
0.19% 1,120 M€ -1.90%
DAIWA ETF MSCI JAPAN ESG SELECT LEADERS INDEX ETF - JPY ETF Daiwa ETF MSCI Japan ESG Select Leaders Index ETF - JPY
0.13% 81 M€ +11.78%
More ETFs positioned on Santen Pharmaceutical Co., Ltd.

Quotes

Date Price Change Volume
24-04-19 1,452 +0.66% 1 632 300
24-04-18 1,443 -0.52% 1,622,000
24-04-17 1,450 +0.69% 1,390,800
24-04-16 1,440 0.00% 1,271,200
24-04-15 1,440 -1.00% 654,300

Delayed Quote Japan Exchange, April 19, 2024 at 02:34 am EDT

More quotes

Company Profile

SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The Company engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The Company operates in Japan, Europe, Asia, North America markets.
Sector
Pharmaceuticals
Calendar
2024-05-08 - Q4 2023 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Santen Pharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
1,443 JPY
Average target price
1,767 JPY
Spread / Average Target
+22.45%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SANTEN PHARMACEUTICAL CO., LTD. Stock Santen Pharmaceutical Co., Ltd.
+3.38% 3.4B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.97% 672B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+23.76% 550B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.02% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+14.85% 317B
ABBVIE INC. Stock AbbVie Inc.
+6.25% 292B
ASTRAZENECA PLC Stock AstraZeneca PLC
+2.37% 211B
NOVARTIS AG Stock Novartis AG
-0.27% 203B
PFIZER, INC. Stock Pfizer, Inc.
-11.81% 144B
AMGEN INC. Stock Amgen Inc.
-8.80% 141B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4536 Stock